In conclusion, our study presented a comprehensive perspective on HER2-low tumor and demonstrated the clinic-pathological characteristics of this newly raised subgroup of breast cancer in a large cohort of early-stage breast cancer patients undergoing neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.